On Friday, Nektar Therapeutics (NASDAQ:NKTR)’s shares inclined 0.25% to $11.83.
Nektar Therapeutics (NKTR) formerly approved, subject to stockholder approval, an amendment to the Company’s 2012 Performance Incentive Plan (the “2012 Plan”) that would enhance the number of shares of the Company’s common stock reserved for issuance under the 2012 Plan by an additional 7,000,000 shares. According to the final results from the Company’s 2015 Annual Meeting of Stockholders held on June 16, 2015 (the “Annual Meeting”), the Company’s stockholders approved the amendment to the 2012 Plan. The foregoing description of the amendment is qualified in its entirety by reference to the text of the amended and restated version of the 2012 Plan, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline comprises drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.
Insys Therapeutics Inc (NASDAQ:INSY)’s shares gained 1.45% to $40.01.
Insys Therapeutics Inc (INSY) declared that Michael L. Babich, President and Chief Executive Officer, and Darryl Baker, Chief Financial Officer, will present at the forthcoming JMP Securities Life Sciences Conference 2015 as follows:
Date: Wednesday, June 24, 2015
Time: 9:00 a.m. EDT
Location: St. Regis Hotel, New York City
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients; and Dronabinol SG Capsule, a dronabinol soft gelatin capsule that is generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. Its products candidates also comprise Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol.
At the end of Friday’s trade, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)‘s shares dipped -0.08% to $11.99.
Ironwood Pharmaceuticals, Inc. (IRWD) declared the pricing of $300 million aggregate principal amount of convertible senior unsecured notes that will mature on June 15, 2022 (the Notes). The Notes are being offered and sold to qualified institutional buyers following Rule 144A under the Securities Act of 1933, as amended. Ironwood has also granted the initial purchasers of the Notes an option to purchase up to an additional $45 million aggregate principal amount of the Notes solely to cover over-allotments.
The Notes will bear cash interest at a rate of 2.25%, payable on June 15 and December 15 of each year, startning on December 15, 2015. The Notes will not be redeemable prior to maturity. The Notes will be convertible, only during certain periods and subject to certain circumstances, into cash, shares of Ironwood Class A common stock, or a combination of cash and shares of Ironwood’s Class A common stock, at Ironwood’s election. The initial conversion rate for the Notes is 60.3209 shares of Ironwood’s Class A common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of about $16.58 per share of Ironwood’s Class A common stock, representing an about 35% conversion premium based on the last stated sale price of Ironwood’s Class A common stock of $12.28 per share on June 9, 2015.
Ironwood Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Constella name in the European Union. It has partnershipagreements with Actavis plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, in addition to in China, Hong Kong, and Macau.
Crocs, Inc. (NASDAQ:CROX), ended its Friday’s trading session with -1.77% loss, and closed at $14.99.
Crocs Inc. (CROX) declared that Carrie Teffner, the executive vice president and chief financial officer for PetSmart, Inc. (PETM), has been designated to its board of directors. Crocs also declared that current director Peter Jacobi is voluntarily retiring from his position. Both changes were effective on June 9, 2015.
Teffner brings more than 27 years of consumer goods and retail leadership experience to Crocs’ board, most recently as the executive vice president and chief financial officer for PetSmart. After joining PetSmart in 2013, Teffner supported the company’s continued growth and evolution, counting its recent sale to a consortium led by London-based BC Partners for $8.7 billion. Prior to her position at PetSmart, Teffner served in the chief financial officer role for Weber-Stephen Products, a manufacturer of grills and grill accessories, and for Timberland, a footwear manufacturer and retailer. Teffner spent the first 21 years of her career in various business and leadership roles for Sara Lee Corporation.
As a member of the Crocs board since 2008, Peter Jacobi has played an integral role in the growth of the company, counting reaching more than $1 billion in annual sales in 2011. His background in business and operations administration has offered important leadership and insights to the company and its board during the past seven years. In addition to his service at Crocs, Jacobi was employed by Levi Strauss & Company from 1970 to 1999, where he was president and chief operating officer from 1996 until his retirement.
Crocs, Inc. designs, develops, manufactures, markets, and distributes casual lifestyle footwear, apparel, and accessories for men, women, and children worldwide. The company designs and sells a range of footwear and accessories that utilize its proprietary closed cell-resin, called Croslite. Its footwear products comprise sandals, sneakers, mules, and flats and boots. Crocs, Inc.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.